CooperCompanies reported third-quarter fiscal 2026 revenue of $1.066 billion, up about 1% on both a reported and organic basis, and concluded its strategic review by deciding to retain CooperSurgical after offers failed to reflect the unit's full value. The Board unanimously determined shareholders are better served by continued ownership than by a transaction at this time, citing temporary factors including a competitive entrant in the non-hormonal IUD market and the impact of the fertility litigation settlement. CooperVision revenue was $717 million, essentially flat year-over-year, as the company proactively reduced U.S. channel inventory, a move that will also weigh on the fourth quarter; underlying U.S. consumption still grew at a mid-single-digit rate. CooperSurgical revenue was $349 million, up 3% organically, with fertility up 5% to $141 million and office and surgical up 2% to $208 million. Non-GAAP EPS rose 4% to $1.15, marking the 11th consecutive quarter above consensus, and free cash flow of $273 million was the highest quarterly figure in Cooper's history; the company repurchased $339 million of shares in the quarter and the Board approved a $1 billion increase to its repurchase authorization, bringing remaining capacity to approximately $1.5 billion. For the fourth quarter, CooperCompanies guided to consolidated revenue of $1.057 billion to $1.08 billion, or 0% to 2% organic growth, and non-GAAP EPS of $1.05 to $1.09, with CooperVision revenue of $692 million to $706 million and CooperSurgical revenue of $364 million to $374 million.
The Cooper Companies, IncConcluded strategic review and will retain CooperSurgical after bids fell short of the unit's full value, a valuation/M&A decision.
